SG Americas Securities LLC Buys 9,904 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

SG Americas Securities LLC increased its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 56.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,483 shares of the company’s stock after buying an additional 9,904 shares during the quarter. SG Americas Securities LLC’s holdings in Nautilus Biotechnology were worth $46,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Barclays PLC grew its stake in Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after acquiring an additional 47,059 shares during the period. MetLife Investment Management LLC acquired a new position in Nautilus Biotechnology in the third quarter valued at about $87,000. The Manufacturers Life Insurance Company bought a new stake in shares of Nautilus Biotechnology in the third quarter valued at about $67,000. Wexford Capital LP lifted its holdings in shares of Nautilus Biotechnology by 9.6% in the third quarter. Wexford Capital LP now owns 228,350 shares of the company’s stock valued at $651,000 after purchasing an additional 20,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Nautilus Biotechnology by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after acquiring an additional 9,404 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Down 0.6 %

Shares of NASDAQ:NAUT opened at $1.71 on Friday. The business has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $2.31. Nautilus Biotechnology, Inc. has a 12-month low of $1.56 and a 12-month high of $3.10. The firm has a market cap of $214.71 million, a P/E ratio of -3.05 and a beta of 1.21.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $2.25 to $1.75 in a research note on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.